BerGenBio

Share Issue/Capital Change • Apr 25, 2023

BerGenBio ASA - Key information relating to the preferential rights issue

BerGenBio ASA - Key information relating to the preferential rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED

STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE

PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT

Reference is made to the stock exchange announcement published by BerGenBio ASA

(the "Company") earlier today, on 25 April 2023, regarding the resolution by the

Company's board of directors to propose that the Company carries out a share

capital increase, by way of a partly underwritten rights issue, to raise gross

proceeds of up to NOK 250 million (the "Rights Issue").

Date on which the terms and conditions of the preferential rights issue were

announced: 25 April 2023

Last day including right: 22 May 2023

Ex-date: 23 May 2023

Record Date: 24 May 2023

Date of approval: 22 May 2023

Maximum number of new shares: 2,500,000,000

Subscription price: Minimum NOK 0.10 and maximum NOK 10

Ratio preferential rights: To be announced when the final number of new shares

is determined

Subscription ratio: To be announced when the final number of new shares is

determined

Managers: Arctic Securities AS and Carnegie AS

Will the rights be listed: The Company will apply for listing of the

preferential rights on the Oslo Stock Exchange

ISIN for the preferential rights: To be announced when clarified

Other information: The subscription price for the new shares to be issued in the

Rights Issue, and thus the final number of new shares and the exact amount of

the share capital increase will be proposed by the board of directors, based on

a recommendation from the managers, the day prior to the annual general meeting

to be held on 22 May 2023 (the "AGM"). See the stock exchange announcement

published earlier today, on 25 April 2023, for further information regarding the

Rights Issue. The rights issue is subject to approval by the AGM. Notice of the

AGM will be sent on 28 April 2023.

This information is published in accordance with the requirements of the

Continuing Obligations.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com.